AXS Investments’s iBio IBIO Stock Holding History

AXS Investments’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-88	Closed	-$46K	–	201
2021 Q3	$46K	Buy	+88	New	+$54.8K	0.02%	98

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AXS Investments's IBIO Position: Q4 2021 in Review

AXS Investments sold out of iBio (IBIO) in Q4 2021, closing a stake of 88 shares — an estimated $46K sold.

AXS Investments first reported a position in IBIO in Q3 2021 and held it in 1 quarter. The position peaked at $46K in Q3 2021. 77 funds tracked by Wall St. Rank hold IBIO as of Q4 2021.

AXS Investments reported no remaining iBio position as of Q4 2021 after selling out during the quarter.
AXS Investments sold 88 iBio shares in Q4 2021, an estimated $46K.
AXS Investments first reported a position in iBio in Q3 2021 and held it in 1 quarter.
AXS Investments's iBio position peaked at $46K in Q3 2021.
77 funds tracked by Wall St. Rank held iBio as of Q4 2021.

Based on AXS Investments's 13F filing for Q4 2021, filed 9 Feb 2022.